Risultati per: JAMA Psychiatry

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

This Viewpoint examines the scarcity of psychiatric success rate trend data and discusses what can be done about it.

The past year saw ongoing impacts from the COVID-19 pandemic as well as new hope for recovery in the world and in our field. At JAMA Psychiatry, we worked hard to set and maintain the highest standards despite ongoing challenges. We published studies on psilocybin-assisted psychotherapy for alcohol use disorder, association of baseline psychopathology with post–COVID-19 conditions, increase in drug overdose mortality rates during the pandemic, and many others on important topics running the gamut from clinical trials and epidemiology to clinical neuroscience and genetics.

This past year has been an exciting one for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing a diverse and interesting array of topics. Diversity in the oncology workforce and disparities in health equity were common topics. Articles ranged from data on lack of access to cancer screening for some populations, to the inability to access health technology, to the role of zip code in cancer care. We continued to receive reports about the COVID-19 pandemic in cancer, including studies that explore the efficacy of specific vaccines on the more aggressive variants of the virus and the role of booster immunizations in enhancing immune responses in patients. We have reported results from several large phase 3 randomized clinical trials affecting standard of care as well as exciting and promising results from smaller phase 1 and 2 studies with outstanding correlative science. We hope that you enjoyed reading these articles as much as we enjoyed choosing the best manuscripts for publication. We thank the many authors, reviewers, and readers for the significant contributions made to the journal this past year. The JAMA Oncology editorial board, editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct effect on researchers, clinicians, and the patients we serve. The impact factor of 33.01 placed JAMA Oncology as one of the highest-ranking oncology journals.

Mission Statement: JAMA Dermatology’s mission is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, to enable dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. The journal also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.

The US enters the fourth year of the COVID-19 pandemic with increasing health care challenges. Medicare is heading toward insolvency, launch prices of new drugs are reaching an all-time high, and Congress is increasingly dysfunctional. At JAMA Internal Medicine, our hard work of promoting high-value health care that is accessible to all is more important than ever. Meanwhile, we are continuing to watch closely the implementation phase of reducing low-value care. The journal’s Less is More series of articles, which is entering its 13th year, is as important as ever. In 2023, we hope to see progress on complex issues such as value-based payment, drug pricing, and transparency of data and regulatory decisions, to name just a few. We continue to inform our readership and propose solutions to increase high-value care.

JAMA Dermatology continued to thrive in 2022. The editorial leadership team carefully evaluated 2745 article submissions during the past year (Table). A total of 1300 of 2745 submissions (47%) were research articles, which was similar to the previous year. Acceptance rates also remained stable, with 10% of submissions overall and 11% of research articles accepted for publication. With an ongoing commitment to publishing excellence and process improvement, the journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 61 days while offering timely editorial decisions, including maintaining its median receipt-to-rejection time of 4 days and median receipt to first decision with peer review of 42 days. The editorial leadership team continued to strive to find ways to improve authors’ experience to ensure authors the fastest and best publication of their work. As predicted in last year’s review, many of the top dermatology journals achieved substantial increases in impact factors, which was likely a reflection of COVID-19 skin-related publications, and in line with trends seen across the medical literature. JAMA Dermatology’s impact factor increased from 10.3 to 11.8.

Mission Statement: To promote the art and science of medicine and the betterment of public health by publishing manuscripts of interest and relevance to internists practicing as generalists or as medical subspecialists.

Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians and researchers in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform its readers, to stimulate discussion into the nature, causes, treatment, and public health importance of mental illness, and to promote equity and justice for those affected by mental illness and for society.

We sincerely thank the 509 peer reviewers who completed manuscript reviews for JAMA Internal Medicine in 2022.

Introduction
Managing violence or aggression is an ongoing challenge in emergency psychiatry. Many patients identified as being at risk do not go on to become violent or aggressive. Efforts to automate the assessment of risk involve training machine learning (ML) models on data from electronic health records (EHRs) to predict these behaviours. However, no studies to date have examined which patient groups may be over-represented in false positive predictions, despite evidence of social and clinical biases that may lead to higher perceptions of risk in patients defined by intersecting features (eg, race, gender). Because risk assessment can impact psychiatric care (eg, via coercive measures, such as restraints), it is unclear which patients might be underserved or harmed by the application of ML.

Methods and analysis
We pilot a computational ethnography to study how the integration of ML into risk assessment might impact acute psychiatric care, with a focus on how EHR data is compiled and used to predict a risk of violence or aggression. Our objectives include: (1) evaluating an ML model trained on psychiatric EHRs to predict violent or aggressive incidents for intersectional bias; and (2) completing participant observation and qualitative interviews in an emergency psychiatric setting to explore how social, clinical and structural biases are encoded in the training data. Our overall aim is to study the impact of ML applications in acute psychiatry on marginalised and underserved patient groups.

Ethics and dissemination
The project was approved by the research ethics board at The Centre for Addiction and Mental Health (053/2021). Study findings will be presented in peer-reviewed journals, conferences and shared with service users and providers.

We sincerely thank the 2371 peer reviewers who completed manuscript reviews for JAMA in 2022.

JAMA is celebrating its 140th year of publication in 2023. As we look to the journal’s future, we take this opportunity to reflect on 2022 and the major milestones that set the direction for us moving forward. We do so with deep gratitude to the authors, peer reviewers, and readers who continue to place their trust in JAMA as a leading journal dedicated to advancing the science of medicine and the health of the public. Three themes punctuate the reflections on 2022.